Continuous Saphenous Block Versus Continuous Femoral Block for Total Knee Arthroplasty

NCT01250041 | Unknown

• 1 other identifier: 10-153-SDR
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

Strength of the Quadriceps Muscle is key to recover from Total Knee Arthroplasty. In this study we compare two techniques for pain control after total knee arthroplasty in terms of preserving the motor function (the strength of the quadriceps muscles of the thigh) which will facilitate the rehabilitation and accelerate the hospital discharge. We will use ultrasound guided technique to block either the femoral nerve in the control group or the saphenous nerve in the experimental group. The primary outcome is the functional capacity and the impact of each block on the ability to walk by measuring the distance patients are able to walk in two minutes in post operative day one in the two groups. The secondary outcome is the morphine consumption in the two groups.

Conditions

Total Knee Arthroplasty Secondary to Osteoarthritis

Outcome Measures

Primary Outcomes (1)

• to assess the functional capacity and the impact of each block on the ability to walk by measuring the distance (the 2 minute walk test) in post op day one in the two groups.

  post op day one

Secondary Outcomes (1)

• the morphine consumption in the two groups.

  post op day one

Study Arms (2)

femoral block

ACTIVE COMPARATOR

Procedure: continuous femoral nerve block

saphenous block

EXPERIMENTAL

Procedure: continuous saphenous nerve block

Interventions

continuous femoral nerve block PROCEDURE

ultrasound guided femoral nerve catheter insertion.

femoral block

continuous saphenous nerve block PROCEDURE

ultrasound guided saphenous nerve catheter insertion

saphenous block

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• \- Subject age over 18 years coming for total knee arthroplasty secondary to osteoarthritis

You may not qualify if:

• ASA 4-5
• Abnormal liver enzymes, hepatic failure, renal failure and cardiac failure if they become contraindication for the use of regional anesthesia
• Contraindications for spinal anesthesia
• Morbid obesity
• Organ transplant
• Neuropathic pain
• History of stroke or major neurological deficit
• Sensory and motor disorders in the operated limb
• Previous drug dependency
• Chronic use of opioids
• Allergy to local anesthetics
• Inability to comprehend pain assessment

Sponsors & Collaborators

• McGill University Health Centre/Research Institute of the McGill University Health Centre: lead

Study Sites (1)

Montreal General Hospital

Montreal, Quebec, H3A 1A1, Canada

Location

Study Officials

• JF Asenjo, MD

  McGill University Health Centre/Research Institute of the McGill University Health Centre

  PRINCIPAL INVESTIGATOR

Central Study Contacts

JF Asengo, MD

CONTACT

(514) 934-1934; jfasenjog@yahoo.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
• Intervention Model: PARALLEL
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: November 26, 2010
• First Posted: November 30, 2010
• Study Start: January 1, 2011
• Primary Completion: August 1, 2011
• Study Completion: December 1, 2011
• Last Updated: November 30, 2010

Record last verified: 2010-11

Locations

CA (1)